- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.03. | Coya Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 19.03. | Coya Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 19.03. | Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results | 92 | Business Wire | HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg)... ► Artikel lesen | |
| 13.02. | Coya Therapeutics secures new patent for Treg therapy | 2 | Investing.com | ||
| 05.02. | Coya Therapeutics Secures Key Financing In Its Fight Against Myriad Diseases | 3 | Benzinga.com | ||
| 19.01. | Coya Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.01. | Coya Therapeutics Plans COYA 302 IND Application In Q2 | 3 | RTTNews | ||
| 04.01. | Coya Therapeutics files to sell 4.69M shares for holders | 3 | Seeking Alpha | ||
| 20.12.23 | Coya Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.12.23 | Dr. Reddy's, Coya Therapeutics Partner on ALS Therapy | 2 | Contract Pharma | ||
| 06.12.23 | Coya Therapeutics, Dr. Reddy's Laboratories Join For Development, Commercialization Of COYA 302 | 296 | AFX News | WASHINGTON (dpa-AFX) - Dr. Reddy's Laboratories SA, subsidiary of Dr. Reddy's Laboratories Ltd. (RDY), and Coya Therapeutics, Inc. (COYA) have entered into a development and license agreement... ► Artikel lesen | |
| 06.12.23 | Coya Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 06.12.23 | Coya Therapeutics, Inc. and Dr. Reddy's Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS) | 311 | Business Wire | Under the Agreement, Dr. Reddy's will obtain commercialization rights for COYA 302 in the United States, Canada, the European Union and the United Kingdom, for patients with ALS COYA will... ► Artikel lesen | |
| 08.11.23 | Coya Therapeutics GAAP EPS of -$0.34 | 1 | Seeking Alpha | ||
| 08.11.23 | Coya Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.11.23 | Coya Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 08.11.23 | Coya Therapeutics, Inc. Provides Business Update and Reports Q3 2023 Unaudited Financial Results | 188 | Business Wire | HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the... ► Artikel lesen | |
| 08.08.23 | Coya Therapeutics, Inc. Provides Business Update and Reports Q2 2023 Unaudited Financial Results | 279 | Business Wire | HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the... ► Artikel lesen | |
| 28.06.23 | Coya Therapeutics, Inc.: Coya Therapeutics to Present Proof-of-Concept Clinical Data for Low-Dose Interleukin-2 (ld IL-2) for the Treatment of Patients with Alzheimer's Disease (AD) at the 2023 Alzheimer's Association International Conference (AAIC) | 444 | Business Wire | The academic proof-of-concept open-label study evaluated the biological activity, cytokine and chemokine blood biomarkers, safety, and preliminary efficacy of low-dose interleukin-2 (ld IL-2)... ► Artikel lesen | |
| 08.06.23 | Coya Therapeutics, Inc.: Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer's Disease | 556 | JCN Newswire | Houston, TX, June 8, 2023 - (ACN Newswire) - Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing multiple therapeutic programs intended... ► Artikel lesen |
Seite:
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,560 | -1,27 % | EQS-News: Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024 | EQS-News: Epigenomics AG
/ Schlagwort(e): Personalie
Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024
30.04.2024 / 15:00 CET/CEST
Für den Inhalt... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 1,020 | +25,00 % | Ist es schon so weit? Raus aus KI, Biotech kaufen: Nvidia, Evotec, Defence Therapeutics und Bayer im Fokus | Wieder ein Schlag ins Kontor! Zum Monatsschluss April stürzt die Technologiebörse Nasdaq zum dritten Mal ab und zeigt mit 17.333 Punkten erneut große Schwäche. Nach einem langen Aufwärtstrend des NDX... ► Artikel lesen | |
| GINKGO BIOWORKS | 0,824 | -2,11 % | Ginkgo Bioworks: Buy, Sell, or Hold? | ||
| BEAM THERAPEUTICS | 22,360 | +2,85 % | Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,435 | +1,14 % | Recursion Pharmaceuticals: Recursion to Participate in Upcoming Investor Conferences | ||
| ONCOLYTICS BIOTECH | 1,060 | +2,91 % | Oncolytics Biotech® Inc.: Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting | SAN DIEGO and CALGARY, AB, April 25, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology,... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 26,520 | -4,95 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| ASSERTIO | 0,999 | +9,30 % | Assertio Holdings, Inc. to Report First Quarter 2024 Financial Results on May 6, 2024 | ||
| SIGA TECHNOLOGIES | 9,260 | -0,64 % | SIGA Technologies Inc.: SIGA Technologies to Host Business Update Call on May 7 Following Release of First-Quarter 2024 Financial Results | ||
| MERRIMACK PHARMACEUTICALS | 15,000 | +0,17 % | Merrimack Pharmaceuticals announces notification of plan to delist common stock on Nasdaq | ||
| VIR BIOTECHNOLOGY | 9,000 | +2,86 % | Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2023.
"Vir... ► Artikel lesen | |
| VERVE THERAPEUTICS | 6,150 | +2,67 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 9,140 | -2,04 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Submits Response for neffy (epinephrine nasal spray) Marketing Authorization Application to EMA's CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand | CHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024 Response addresses all issues previously identified by CHMP, and includes results from a repeat... ► Artikel lesen | |
| BIO-PATH | 2,780 | +4,12 % | Looking Into Bio-Path Holdings' Recent Short Interest | ||
| BIOMEA FUSION | 11,750 | +1,56 % | Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) ("Biomea" or the "Company"), a clinical stage biopharmaceutical company focused on the discovery and development... ► Artikel lesen |
Das Unternehmen COYA THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,030 (+0,35 %) liegt der Kurs bei 8,700 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
